Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
polifeprosan 20 with carmustine implant
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADELĀ® Wafer in Patients With Metastatic Brain Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GLIA-001
, NCT00525590
2.
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
Other
Protocol IDs:
MHIRB #2007-040
, NCT00548938
3.
Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
200408035
, NCT00574964
4.
A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
KARE003
, KARE 003, NCT00660283
5.
A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
KARE004
, KARE004, NCT00660621
6.
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
00006308
, NCT00735436
7.
Phase II Randomized Study of Intralesional Lymphokine-Activated Killer Cells Versus Polifeprosan 20 With Carmustine Implant (GliadelĀ® Wafer) as Consolidation Therapy After Primary Therapy in Patients With Newly Diagnosed Resectable Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HOAG-HCC-08-01
, HCC 08-01, NCT00814593
8.
Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
07090991
, NCT00645385
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute